Table 3.
Univariate and multivariate Cox proportional hazard regression analysis of patients' overall survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
| Age (years) (≤50 versus >50) | 1.087 | 0.635–1.861 | 0.761 | |||
| Gender (female versus male) | 1.204 | 0.691–2.098 | 0.512 | |||
| HBsAg (negative versus positive) | 0.991 | 0.541–1.816 | 0.977 | |||
| Cirrhosis (absent versus present) | 1.155 | 0.658–2.028 | 0.615 | |||
| AFP (ng/ml) (≤20 versus >20) | 0.905 | 0.534–1.534 | 0.710 | |||
| Tumour size (cm) (≤5 versus >5) | 1.246 | 0.733–2.116 | 0.416 | |||
| Tumour capsule (incomplete versus complete) | 1.178 | 0.684–2.029 | 0.554 | |||
| Vascular invasion (absent versus present) | 0.341 | 0.196–0.592 | <0.001 | 0.780 | 0.290–2.102 | 0.624 |
| Edmondson grade (I/II versus III/IV) | 1.020 | 0.594–1.754 | 0.942 | |||
| Status of metastasis (absent versus present) | 0.298 | 0.171–0.522 | <0.001 | 1.808 | 0.589–5.548 | 0.300 |
| ECOG‐PS (≤0 versus >1) | 0.489 | 0.288–0.830 | 0.008 | 0.652 | 0.261–1.630 | 0.361 |
| TNM stage (I/II versus III/IV) | 0.180 | 0.099–0.326 | <0.001 | 5.173 | 2.661–10.059 | <0.001 |
| BCLC stage (A/B versus C/D) | 0.426 | 0.248–0.730 | 0.002 | 2.625 | 1.294–5.324 | 0.007 |
| CD68‐positive macrophages (low versus high) | 0.636 | 0.376–1.077 | 0.092 | |||
| CD11c‐positive macrophages (low versus high) | 2.128 | 1.241–3.649 | 0.006 | 0.178 | 0.086–0.367 | <0.001 |
| CD206‐positive macrophages (low versus high) | 0.447 | 0.263–0.760 | 0.003 | 1.943 | 1.062–3.552 | 0.031 |
CI: confidence interval; HR: hazard's ratio; HBsAg: hepatitis B surface antigen; AFP: alpha‐fetoprotein; ECOG‐PS: Eastern Cooperative Oncology Group performance status; TNM: tumour–node–metastasis; BCLC: Barcelona Clinic Liver Cancer.